Pruritus caused by skin diseases
Conditions
Interventions
experimental group:Shiduqing Capsules/Shiduqing Tablets
Sponsors
Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 4.2.1 Aged 18 to 75, of either gender; 4.2.2 Patients with clinically diagnosed skin itching-related diseases (including atopic dermatitis, psoriasis, urticaria, chronic eczema, nodular prurigo, neurodermatitis, and cutaneous pruritus), with a clear diagnosis of Fengshi Yunfu syndrome or Xuexu Fengzao syndrome in traditional Chinese medicine (TCM), and who have been prescribed Shiduqing by a doctor based on clinical routine diagnosis and treatment decisions; 4.2.3 Voluntarily sign the informed consent form and promise to cooperate in completing the required follow-up visits and data collection; 4.2.4 Able to articulate their own itching sensations clearly, and capable of completing the VAS scoring and questionnaire filling (or with the assistance of family members); 4.2.5 At baseline (before medication), the VAS itch score is =4 (indicating moderate or severe itch).
Exclusion criteria
Exclusion criteria: 4.3.1 Those who are allergic to any component of Shiduqing (such as Rehmannia glutinosa, Angelica sinensis, Sophora flavescens, etc.) or excipients of the preparation (such as gelatin in capsule shells, starch in tablets); 4.3.2 Combined severe organ dysfunction involving the heart, liver, kidney, hematopoietic system, etc. (e.g., ALT/AST > 2 times the upper limit of normal, Scr > 1.5 times the upper limit of normal); 4.3.3 Women who are pregnant or breastfeeding; 4.3.4 Those with a history of drug abuse, alcohol dependence, or mental illness (such as depression, schizophrenia), who are unable to cooperate with follow-up visits; 4.3.5 Those who are currently participating in other drug clinical trials or have participated in other clinical trials within the past 3 months; 4.3.6 Individuals with allergic constitution (allergic to 2 or more drugs or foods) or those who have experienced severe allergic reactions recently (within 1 month); 4.3.7 The researcher believes that there are other situations that are not suitable for inclusion (such as expected survival time < 3 months, inability to complete follow-up, incomplete data, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Analog Scale;Itch Assessment Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Traditional Chinese Medicine (TCM) syndrome score;Body Surface Area;Physician's Global Assessment;Dermatology Life Quality Index score;Hospital Anxiety and Depression Scale; | — |
Countries
China
Contacts
Public ContactChen Weiwen
Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
Outcome results
None listed